Gelonghui, January 15 | China Medical Group (08225.HK) announced that CHG China Medical Group affiliates have reached clinical research and promotion cooperation agreements with Yueyang Xinhuada Pharmaceutical Co., Ltd. and Shandong Langnuo Pharmaceutical Co., Ltd. on children's psychosocial treatment drugs. The above cooperation will play a strong role in promoting the company's business development.
With the release of the “Childhood Mental and Mental Disorders Report”, it has been shown that more and more students are facing mental disorders, and 17.5% of students in the 6-16 age group have mental disabilities. Many of China's top pediatric clinical research centers are full, and the medical market is in huge demand. In this context, the Xixin RWS Center, as a leading clinical research center for mental and mental diseases in China, has reached cooperation with Yueyang Xinhuada Pharmaceutical Co., Ltd. and Shandong Langnuo Pharmaceutical Co., Ltd. to jointly promote the development and promotion of children's psychosocial drugs.
Driven by the three core drivers of real-world clinical research RWS, medical big data RWD, and artificial intelligence, CHG China Medical Group provides life sciences with “research specialty” CHGMyD services, “pharmaceutical clinical research” CHGRWS services, and “scientific research product promotion” CRS0 services in the restructured trillion-dollar drug promotion market. On the basis of curing the two major centuries-old diseases focusing on brain science and allergic reactions, we have built five major specialty brands: Bai Min's Anti-Allergy, Joy's Mental Spirituality, Xien's Prevention of Dementia, Yue Quitting Smoking Addiction, and the rare disease ALS. This cooperation will bring more development opportunities and business expansion space to the Group, and promote the Group's innovation and development in the field of child psychotherapy. At the same time, it also injects new vitality into the development of the Chinese medical market, providing more patients with higher quality and more efficient treatment plans and services